BioSig Technologies

264 articles about BioSig Technologies

• BioSig Appoints Former Qorvo CFO as Successor to Steve Chaussy

  2/7/2023

  BioSig Technologies, Inc. today announced the retirement of chief financial officer Steve Chaussy following a distinguished career with the Company, and has named Steve Buhaly as his successor. 

• BioSig Issues Shareholder Update to Highlight Recent Achievements and Ongoing Developments

  1/19/2023

  To date, the Company's FDA 510(k)-cleared PURE EP™ System has been used in approximately 3,000 patient cases across the United States.

• BioSig Executes Agreement with Bellin Health for the Acquisition of its PURE EP™ Technology

  1/10/2023

  BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”) an advanced digital signal processing technology company delivering unprecedented accuracy and precision to intracardiac signal visualization with its proprietary PURE EP™ System, today announced that Bellin Health System in Green Bay, Wisconsin has signed an agreement to acquire the Company’s PURE EP™ System.

• Update: BioSig’s PURE EP™ System Demonstrates Potential Time and Cost Savings at the 15th APHRS Scientific Session in Singapore

  12/14/2022

  BioSig Technologies, Inc. announced that its PURE EP™ System was featured in an abstract presentation during the 15th Asia Pacific Heart Rhythm Society Scientific Session in Singapore.

• BioSig’s PURE EP™ System Demonstrates Potential Time and Cost Savings at the 15th APHRS Scientific Session in Singapore Abstract highlights promising results from PURE EP™ study at premier Asia-Pacific Heart Rhythm Society Conference

  12/14/2022

  BioSig Technologies, Inc. announced that its PURE EP™ System was featured in an abstract presentation during the 15th Asia Pacific Heart Rhythm Society Scientific Session in Singapore.

• BioSig’s PURE EP™ System Highlighted in the Journal of Atrial Fibrillation & Electrophysiology

  12/6/2022

  BioSig Technologies, Inc announced that a peer-reviewed case report titled, “Confirmation of Acute Pulmonary Vein Reconnection with The Utilization of PURE EP’s High-Frequency Algorithm ” has been published in the Journal of Atrial Fibrillation & Electrophysiology.

• BioSig Signs Master Research Agreement with Cleveland Clinic to Explore Expanded Applications for its Digital Signal Processing Technology

  10/24/2022

  BioSig Technologies, Inc. announced that it will sponsor a research agreement with Cleveland Clinic Foundation to investigate expanded clinical applications for the intracardiac signals acquired by its PURE EP™ System.

• BioSig Invited to Attend and Sponsor Venice Arrhythmias 2022

  10/12/2022

  BioSig Technologies, Inc. today announced that it has been invited to attend the 17th Edition Venice Arrhythmias 2022 Congress—a Heart Rhythm Society sponsored program taking place from October 13-15, 2022 in Venice, Italy.

• BioSig Executes Purchase Agreement with Methodist Hospital, San Antonio and Expands Customer Base

  10/7/2022

  BioSig Technologies, Inc. an advanced digital signal processing technology company delivering unprecedented accuracy and precision to intracardiac signal visualization with its proprietary PURE EP™ System, announced that San Antonio Methodist Hospital has acquired the PURE EP™ System.

• BioSig Launches PURE EP™ Software Version 6 with ACCUVIZ™ Module

  9/22/2022

  BioSig Technologies, Inc. today announced the release of PURE EP™ Software Version 6 with ACCUVIZ™ Module.

• Taglich Brothers Initiates Coverage of BioSig Technologies, Inc.

  9/16/2022

  Taglich Brothers, Inc. announces it has initiated coverage of BioSig Technologies, Inc.

• BioSig Strengthens Marketing and Sales Teams, Appoints National Account Executives to Scale Commercial Growth

  8/30/2022

  BioSig Technologies, Inc., a medical technology company advancing electrophysiology workflow by delivering greater intracardiac signal fidelity through its proprietary signal processing platform, announced that it has expanded its marketing and sales teams to scale and support the national commercial rollout of its PURE EP™ System.

• BioSig Places Second PURE EP™ System For Evaluation at Cleveland Clinic a Leading Medical Center of Excellence

  8/24/2022

  BioSig Technologies, Inc. (NASDAQ: BSGM) ("BioSig" or the "Company"), a medical technology company advancing electrophysiology workflow by delivering greater intracardiac signal fidelity through its proprietary signal processing platform, today announced that it has installed a second evaluation system at the Cleveland Clinic.

• BioSig’s Cardiac Signal Processing Technology To Be Featured at Kansas City Heart Rhythm Symposium 2022 Leading Medical Center of Excellence Physician will discuss integrating the PURE EP™ System into their practice and procedural workflow

  8/17/2022

  BioSig Technologies, Inc. (NASDAQ: BSGM) ("BioSig" or the "Company"), a medical technology company advancing electrophysiology workflow by delivering greater intracardiac signal fidelity through its proprietary signal processing platform, today announced  its participation in the Kansas City Heart Rhythm Symposium, being held on August 20-21, 2022.

• BioSig Sees Positive Momentum from Sales Pipeline Growth

  8/16/2022

  BioSig Technologies, Inc. announced that it is seeing positive momentum from the growth of its sales pipeline, and expects to see an increase in enterprise adoption of its PURE EP™ System in the coming months.

• BioSig Announces Physician-Initiated Research Protocol at The Kansas City Heart Rhythm Institute Led by Dhanunjaya DJ Lakkireddy, MD., the study will investigate expanded applications for the signals acquired by BioSig’s PURE EP(T.M.) System

  7/21/2022

  BioSig Technologies, Inc. announced that Dhanunjaya DJ Lakkireddy, MD, Medical Director for the Kansas City Heart Rhythm Institute, will initiate a research protocol analyzing the signals acquired by the PURE EP System during Radiofrequency ablation.

• BioSig Announces Purchase Agreement with Kansas City Heart Rhythm Institute at Overland Park Regional Medical Center

  7/7/2022

  BioSig Technologies, Inc. today announced that Kansas City Heart Institute at Overland Park Regional Medical Center in Kansas City, U.S. has signed a purchase agreement to acquire its PURE EP(T.M.) System. 

• BioSig Announces Closing of Public Offering of Common Stock - June 29, 2022

  6/29/2022

  BioSig Technologies, Inc. a medical technology company advancing electrophysiology workflow by delivering greater intracardiac signal fidelity through its proprietary signal processing platform, announced the closing and funding of its previously announced best efforts underwritten public offering.

• BioSig Announces Pricing of Public Offering of Common Stock - June 24, 2022

  6/24/2022

  BioSig Technologies, Inc. announced pricing of its previously-announced best efforts underwritten public offering of up to 4,666,667 shares of its common stock, $0.001 par value per share, at a price to the public of $0.75 per share.

• BioSig Announces Proposed Public Offering of Common Stock - June 23, 2022

  6/23/2022

  BioSig Technologies, Inc., a medical technology company commercializing an innovative biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, announced that it intends to offer shares of its common stock in a “best efforts” underwritten public offering.